Japan’s FY2024 pharmaceutical sales revealed a sharp divergence among immune checkpoint inhibitors as MSD’s Keytruda (pembrolizumab) surged toward the 200-billion-yen…
BUSINESS
GMP Deviation at CMO Katsuyama Caused Viatris Shipment Halt
A GMP deviation at contract manufacturer Katsuyama Pharmaceuticals has been identified as the reason behind the recent suspension of five Viatris Pharmaceuticals Japan products, including its irritable bowel syndrome drug Polyful Tablets (polycarbophil calcium). Katsuyama admitted the GMP deviation to…
To read the full story
Related Article
BUSINESS
- Taiho’s DMD Drug TAS-205 Falls Short in PIII Trial
July 9, 2025
- JCR Licenses Gene Therapy Platform to Alexion
July 9, 2025
- Japan’s CAR-T Market Set to Double by 2030, Hitting 39 Billion Yen: Fuji Keizai
July 9, 2025
- Japan Ethical Drug Sales Up 0.5% in May: Crecon
July 9, 2025
- ASKA Targets 30% Overseas Sales Ratio through Southeast Asia Expansion: New President
July 9, 2025
I recently attended a fantastic conference hosted by Prospection Japan, and one speaker, Dr. Joe Ledsam, really blew me away with his insights. He shared some truly fascinating developments about how AI is set to revolutionize healthcare, from how doctors…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…